Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04814511
Other study ID # ETSKABI
Secondary ID 2019-003234-16
Status Recruiting
Phase Phase 3
First received
Last updated
Start date June 11, 2021
Est. completion date August 2023

Study information

Verified date August 2021
Source Infectopharm Arzneimittel GmbH
Contact Andreas Linke, Dr.
Email studien@infectopharm.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The ETSKABI study is a prospective, open-label, multicenter, initially single-armed and in case of treatment failure subsequently three-armed randomized clinical trial. Within the initial treatment phase, the to-date clinical efficacy of the standard therapy regimen according to the current German "S1-guideline for the diagnosis and treatment of scabies" is to be examined. The subsequent second phase focusses on three differently escalated treatment regimens in order to evaluate their potential to cure those patients still suffering from Scabies after standard therapy. In total, 183 patients with Scabies who meet all inclusion criteria and do not meet none of the exclusion criteria are to be enrolled and topically treated with Permethrin 5 % cream (up to two administrations, i.e. repeated one-time on day 14 in case of persisting Scabies). In case of treatment failure by the end of phase one, adult patients will be randomized to either receive an (i) escalated therapy with Permethrin 5 % cream (repeated topical administration on two consecutive days), (ii) an add-on-combination consisting of escalated therapy with Permethrin 5 % cream and Ivermectin p.o. or (iii) an escalated therapy with Permethrin 10 % cream (up to two administrations, i.e. repeated one-time on day 14 in case of persisting Scabies). The primary objective of the ETSKABI study is the clinical efficacy of the standard therapy by the end of phase one (standard therapy according to the S1-guideline). Beside this, clinical efficacy by the end of phase two (escalation phase) will be evaluated as well as adverse events in order to investigate over-all clinical safety.


Recruitment information / eligibility

Status Recruiting
Enrollment 183
Est. completion date August 2023
Est. primary completion date December 2022
Accepts healthy volunteers No
Gender All
Age group 6 Years to 85 Years
Eligibility Inclusion Criteria: - Confirmed acute scabies disease: detection of mites and/or mite nymphs and/or mite larvae at scabies-typical predilection sites, detected by reflected light microscopy (dermatoscopy) or light microscopy of skin samples. - Age between 6 and 85 years - Written informed consent of the study participant (if of age) or of all guardians (in the case of study participants who are minors < 12 years of age) or of all guardians and the study participant (in the case of study participants who are minors = 12 years of age). Exclusion Criteria: - Previous treatment with antiscabiosa in the last 14 days. - Known intolerance to permethrin, other pyrethroids, chrysanthemum, ivermectin or any of the other ingredients of the study medication. - Scabies crustosa - Impetiginisation/eczematisation requiring in-patient treatment - Body weight > 120 kg - Pregnancy, lactation - Immunodeficiency (of any kind, including extensive local therapy (>20% body surface area) with corticosteroids >2 weeks in the last 4 weeks or = 10 mg prednisolone equivalent >7 days in the last 4 weeks- even without signs of scabies crustosa) - Other serious illnesses which, in the opinion of the investigator, prevent the patient from participating in the study (including risk factors for severe COVID-19 disease in the case of SARS-CoV-2 infection). - Planned systemic use of corticosteroids - Planned or previous (last 4 weeks) use of systemic or cutaneous non-steroidal immunosuppressants - Known or clinically suspected blood-brain barrier disruption (e.g. ABCB-1 (=MDR-1) mutation), and history of neurotoxic effects from ivermectin or other substrates/inhibitors of para-glycoprotein (P-gp) - Apparent unreliability or unwillingness to cooperate. - Inability to understand and comply with study instructions - Known alcohol, medication or drug dependence - Court/agency-ordered institutionalisation - Dependence on sponsor or investigator - Previous participation in a clinical trial within the last 30 days or in the same clinical trial

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
InfectoScab 5 % Creme
InfectoScab 5 % Creme is the already approved standard therapeutic agent, containing the active ingredient permethrin in 5 % concentration. In this study, it is used for topical treatment in the first treatment cycle (standard therapy) as well as in the second treatment cycle (escalation therapy).
Permethrin 10 % Creme
Permethrin 10 % Creme also contains permethrin as the active ingredient, but in 10 % concentration. Permethrin 10 % creme is used exclusively for topical treatment in the second therapy cycle (escalation therapy).
Driponin 3 mg Tabletten
Driponin 3 mg Tabletten are approved for the treatment of scabies, containing ivermectin as the active ingredient. Driponin is used as a supplementary, peroral add-on combination treatment in addition to topical permethrin therapy and is used exclusively in the second treatment cycle (escalation therapy).

Locations

Country Name City State
Germany Uniklinik RWTH Aachen Aachen
Germany Universitätsklinikum Augsburg Augsburg
Germany Klinikum Darmstadt Darmstadt
Germany Städtisches Klinikum Dresden Dresden
Germany Universitätsklinik und Poliklinik für Dermatologie und Venerologie Halle (Saale)
Germany Klinikum der Stadt Ludwigshafen Ludwigshafen
Germany Universitätsmedizin Rostock Rostock
Germany Universitätsklinikum Würzburg Würzburg

Sponsors (2)

Lead Sponsor Collaborator
Infectopharm Arzneimittel GmbH Winicker Norimed GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy (Yes/No) Efficacy (Yes/No) after completed standard therapy treatment cycle (InfectoScab 5 % Creme, up to two administrations, if necessary), i.e. treatment success on day 14 (one administration) or on day 28 (one readministration due to persisting Scabies on day 14).
Treatment success is defined as:
absence of new scabietic skin lesions, AND
all remaining scabietic lesions are in healing, AND
exclusion of mite infestation in all non-healed efflorescences by reflected light microscopy (dermatoscope), possibly confirmed by microscopic examination of a skin sample, AND
exclusion of the usage of other anti-scabietic drugs
day 0 - day 28
Secondary Efficacy (treatment success) for VS1 and VS2, as well as for the corresponding follow-up visits FUS1 and FUS2 (separately and cumulatively). day 14 - day 70
Secondary Efficacy (therapy success) for VE5, VE101/2 (separately and cumulatively) and VEK as well as for the corresponding follow-up visits FUE5/E10/EK, separately as well as cumulatively according to visit type (regular visit, FU visit) day 28 - day 70
Secondary Cumulative efficacy (treatment success) of permethrin-only treatment (i.e. without combined escalation permethrin + ivermectin) by visit type (regular visit, FU visit) day 28 - day 56
Secondary Frequency of required repeated standard therapy as well as escalated therapy. day 0 - day 70
Secondary Itch (numerical rating scale (NRS) of 0-10) and change in itch vs baseline (scale differences) for all visits, for standard therapy and escalated therapy, and for escalated therapy additionally the change in itch vs start of escalated therapy. day 0 - day 70
Secondary Number and type of body regions affected (wrists/hands, arm pouches, armpits, genital region, groin, knee, feet/ankles/lower legs, head, torso, other) for all visits. day 0 - day 70
Secondary Proportion of patients (in %) with evidence of mites (incl. nymphs and larvae, reflecting light microscopy (dermatoscope) or light microscopy of skin samples) for all visits, for standard therapy and escalated therapy day 0 - day 70
Secondary Proportion of patients with use of antiscabiosa not conforming to study procedures for all visits, for standard therapy and escalated therapy day 0 - day 70
Secondary Proportion of patients with new scabies efflorescences for all treatment cycles and control visits day 0 - day 70
Secondary Patients with "additionally confirmed" therapy failure (in %) Proportion of patients with new scabies efflorescences at the end of standard therapy or escalated therapy OR with mite detection by microscopic examination of a skin sample at the aforementioned time points OR use of other antiscabiosa not conforming to the study procedure during the respective therapy cycle. day 0 - day 70
Secondary Patients with reinfestation (in %): Proportion of patients with microscopically confirmed new efflorescences at the end of standard therapy or escalated therapy (respective FU-visit) who were assessed as cured at the immediately preceding control visit. day 0 - day 70
Secondary Adverse events, serious adverse events, unexpected drug reactions, serious unexpected drug reactions (total frequency, type, severity, causality, with frequencies, with separate presentation of local reactions). day 0 - day 70
See also
  Status Clinical Trial Phase
Completed NCT02572986 - A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies Phase 3
Completed NCT00884728 - Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory N/A
Completed NCT05025696 - Efficacy and Side Effects of Blacksoap® as Adjuvant Therapy of Scabies N/A
Completed NCT04205669 - Comparing the Effectiveness of Individual vs. Household Treatment for Scabies in Lambaréné, Gabon Phase 4
Completed NCT02254564 - PCR (Polymerase Chain Reaction) Assay for Diagnosis of Sarcoptes Scabiei
Not yet recruiting NCT06404333 - Evaluating Pediatric Ivermectin in Children Under 15 kg (EPIC-15) Phase 2
Completed NCT03676140 - Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Phase 3
Recruiting NCT05875441 - Efficacy and Safety Study of Moxidectin in Adults With Scabies Phase 2
Completed NCT02978508 - Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies. Phase 3
Recruiting NCT04332068 - Ivermectin Safety in Small Children Phase 2
Recruiting NCT04844905 - Adjunctive Ivermectin Mass Drug Administration for Malaria Control Phase 3
Not yet recruiting NCT06380452 - Therapy for Scabies With Two Differently Concentrated Permethrin Creams Phase 3
Completed NCT00604084 - Veron Scabies Education and Eradication Program N/A
Completed NCT02485717 - Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies Phase 3
Completed NCT02485704 - Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies Phase 3
Recruiting NCT05310734 - PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Scabies Phase 4
Recruiting NCT04931680 - Risk Factors for Treatment Failure of Scabies in Autochthonous Populations of French Guiana (GUYAGALE)
Completed NCT06396507 - Sulfur vs. Different Regimes of Permethrin for Scabies Phase 3
Completed NCT05862701 - Comparison of Topical 5% Permethrin and Topical 10% Sulfur in the Treatment of Scabies Phase 1
Not yet recruiting NCT05500326 - Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study) Phase 2